Scinai Immunotherapeutics Ltd
SCNI1.510USD
+0.040+2.72%
Fechamento 08/04, 16:00（ET）Cotações atrasadas em 15 min
1.29MValor de mercado
0.34P/L TTM
Mais detalhes de Scinai Immunotherapeutics Ltd Empresa
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
Informações da empresa
Código da empresaSCNI
Nome da EmpresaScinai Immunotherapeutics Ltd
Data de listagemJun 07, 2007
CEOMr. Amir Reichman
Número de funcionários31
Tipo de títulosDepository Receipt
Fim do ano fiscalJun 07
EndereçoJerusalem Biopark, 2Nd Floor
CidadeJERUSALEM
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal00000
Telefone97289302529
Sitehttps://www.scinai.com/
Código da empresaSCNI
Data de listagemJun 07, 2007
CEOMr. Amir Reichman
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
8.08K
+236.54%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
1.27K
--
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
276.00
--
Mr. Adi Raviv
Mr. Adi Raviv
External Director
External Director
50.00
+51.52%
Prof. Avner Rotman
Prof. Avner Rotman
Director
Director
50.00
-26.47%
Dr. Yael Margolin
Dr. Yael Margolin
External Director
External Director
50.00
+51.52%
Mr. Samuel J. Moed
Mr. Samuel J. Moed
Director
Director
--
--
Mr. Joshua Phillipson
Mr. Joshua Phillipson
Investor Relations
Investor Relations
--
--
Dr. Morris C. Laster, M.D.
Dr. Morris C. Laster, M.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Amir Reichman
Mr. Amir Reichman
Chief Executive Officer, Director
Chief Executive Officer, Director
8.08K
+236.54%
Dr. Tamar Ben-Yedidia
Dr. Tamar Ben-Yedidia
Chief Scientific Officer
Chief Scientific Officer
1.35K
--
Mr. Elad Mark
Mr. Elad Mark
Chief Operating Officer
Chief Operating Officer
1.27K
--
Mr. Uri Ben-Or, CPA
Mr. Uri Ben-Or, CPA
Chief Financial Officer
Chief Financial Officer
276.00
--
Mr. Adi Raviv
Mr. Adi Raviv
External Director
External Director
50.00
+51.52%
Prof. Avner Rotman
Prof. Avner Rotman
Director
Director
50.00
-26.47%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 28 de mai
Atualizado em: qua, 28 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Yorkville Advisors Global, LP.
10.93%
LCK JNK 1 LLC
9.47%
Stone (Daniel E)
7.32%
Armistice Capital LLC
5.25%
Abalone Asset Management Ltd.
4.99%
Other
62.04%
Investidores
Investidores
Proporção
Yorkville Advisors Global, LP.
10.93%
LCK JNK 1 LLC
9.47%
Stone (Daniel E)
7.32%
Armistice Capital LLC
5.25%
Abalone Asset Management Ltd.
4.99%
Other
62.04%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
14.34%
Corporation
9.47%
Individual Investor
8.75%
Investment Advisor
6.93%
Hedge Fund
5.25%
Research Firm
0.02%
Other
55.24%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
32
381.87K
44.77%
+269.77K
2025Q1
34
424.61K
49.78%
+268.71K
2024Q4
29
225.02K
26.38%
+113.05K
2024Q3
33
172.68K
20.39%
+41.77K
2024Q2
34
145.50K
9.79%
-4.50K
2024Q1
37
164.38K
100.97%
+8.82K
2023Q4
39
169.63K
48.24%
+28.24K
2023Q3
42
134.35K
45.97%
+54.60K
2023Q2
41
94.79K
37.87%
-787.00
2023Q1
43
111.61K
43.64%
+31.95K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Yorkville Advisors Global, LP.
93.27K
10.93%
+93.27K
--
Mar 24, 2025
LCK JNK 1 LLC
80.76K
9.47%
+80.76K
--
Feb 09, 2025
Stone (Daniel E)
62.40K
7.32%
--
--
Dec 31, 2024
Armistice Capital LLC
44.80K
5.25%
+44.80K
--
Sep 30, 2024
Abalone Asset Management Ltd.
42.54K
4.99%
+24.54K
+136.35%
Jun 30, 2024
Sabby Management, LLC
29.05K
3.41%
+29.05K
--
Dec 31, 2024
UBS Financial Services, Inc.
14.93K
1.75%
-8.56K
-36.43%
Mar 31, 2025
Reichman (Amir)
8.08K
0.95%
+5.68K
+236.54%
Mar 31, 2025
Rhumbline Advisers Ltd. Partnership
1.57K
0.18%
-86.00
-5.20%
Mar 31, 2025
Ben-Yedidia (Tamar)
1.35K
0.16%
+1.35K
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
SPDR Portfolio Developed World ex-US ETF
0%
SPDR Portfolio Developed World ex-US ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
Nov 23, 2022
Merger
10<1
Nov 23, 2022
Merger
10<1
Data
Tipo
Proporção
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
May 06, 2024
Merger
10<1
Nov 23, 2022
Merger
10<1
Nov 23, 2022
Merger
10<1
Nov 23, 2022
Merger
10<1
Nov 23, 2022
Merger
10<1
